Phase I/II Study of Venetoclax in Combination With Ublituximab and Umbralisib (TGR-1202) in Patients With Relapsed or Refractory CLL/SLL
Phase of Trial: Phase I/II
Latest Information Update: 11 Oct 2018
At a glance
- Drugs Ublituximab (Primary) ; Umbralisib (Primary) ; Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- Sponsors TG Therapeutics Inc
- 30 Apr 2018 Planned End Date changed from 1 Aug 2020 to 1 Dec 2021.
- 30 Apr 2018 Planned primary completion date changed from 1 Aug 2019 to 1 Aug 2021.
- 24 Apr 2018 Status changed from not yet recruiting to recruiting.